|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Osteosarcoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we performed a global transcriptional analysis using gene array technology to investigate the transcriptional role of CDK11 in osteosarcoma.
|
31610798 |
2019 |
|
Osteosarcoma of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we performed a global transcriptional analysis using gene array technology to investigate the transcriptional role of CDK11 in osteosarcoma.
|
31610798 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
These data establish CBFβ as a mediator of CDK11<sup>p110</sup> dependent oncogenesis and suggest that targeting the CDK11- CBFβ pathway may be a promising therapeutic strategy for osteosarcoma treatment.
|
31610798 |
2019 |
|
Childhood Osteosarcoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we performed a global transcriptional analysis using gene array technology to investigate the transcriptional role of CDK11 in osteosarcoma.
|
31610798 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The genome editing mediated by the nanoparticles leads to a dramatic decrease (>75%) in CDK11 expression, which results in further modulation of cancer cells with significant down-regulation of the proteins (MMP-9 and VEGF) involved in tumor development and metastasis as well as up-regulation of the tumor suppressor protein p53.
|
30339905 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
On the basis of the tumor cell targeting capability of biotin and AS1411 ligands as well as the nuclear targeting of AS1411, the dual-targeting system can deliver the CRISPR-Cas9 plasmid into the nuclei of tumor cells to realize highly efficient genome editing, resulting in a dramatic decrease (>90%) in CDK11 protein together with the significant downregulation of other proteins involved in tumor development, including an ∼90% decrease in MMP-9, >40% decrease in VEGF, and ∼70% decrease in survivin.
|
29617556 |
2018 |
|
Osteosarcoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
|
30093700 |
2018 |
|
Osteosarcoma of bone
|
0.040 |
Biomarker
|
disease |
BEFREE |
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
|
30093700 |
2018 |
|
Childhood Osteosarcoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.
|
30093700 |
2018 |
|
Osteosarcoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDK11 increased transcriptional activation of AR gene in osteosarcoma cell lines.
|
28262798 |
2017 |
|
Osteosarcoma of bone
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDK11 increased transcriptional activation of AR gene in osteosarcoma cell lines.
|
28262798 |
2017 |
|
Childhood Osteosarcoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDK11 increased transcriptional activation of AR gene in osteosarcoma cell lines.
|
28262798 |
2017 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
However, the function of CDK11 larger protein isomer, CDK11(p110), in the tumorigenesis of human breast cancer remains unclear.
|
25990212 |
2015 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CDK11(p58), a Ser/Thr kinase that belongs to the Cell Division Cycle 2-like 1 (CDC2L1) subfamily is associated with cell cycle progression, tumorigenesis, sister chromatid cohesion and apoptotic signaling.
|
26470709 |
2015 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CDK11(p58), a Ser/Thr kinase that belongs to the cell division cycle 2-like 1 (CDC2L1) subfamily, is associated with cell cycle progression, tumorigenesis and apoptotic signaling.
|
25106495 |
2014 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Systemic in vivo administration of in vivo ready siRNA of CDK11 reduced the tumor growth in an osteosarcoma subcutaneous xenograft model.
|
22791884 |
2012 |
|
Osteosarcoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDK11 expression knocked down by either lentiviral shRNA or siRNA inhibit cell growth and induce apoptosis in osteosarcoma cells.
|
22791884 |
2012 |
|
Osteosarcoma of bone
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDK11 expression knocked down by either lentiviral shRNA or siRNA inhibit cell growth and induce apoptosis in osteosarcoma cells.
|
22791884 |
2012 |
|
Childhood Osteosarcoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDK11 expression knocked down by either lentiviral shRNA or siRNA inhibit cell growth and induce apoptosis in osteosarcoma cells.
|
22791884 |
2012 |
|
Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Thus, we showed that the neuroblastoma tumour suppressor critical region on 1p in our material is defined by loci D1S244 and D1S80 and that the CDC2L1 locus is distal to the critical region.
|
9516841 |
1997 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CDK11 and CK2 expression are individually essential for breast cancer cell survival, including TNBC.
|
25837326 |
2015 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
However, the function of CDK11 larger protein isomer, CDK11(p110), in the tumorigenesis of human breast cancer remains unclear.
|
25990212 |
2015 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
However, the function of CDK11 larger protein isomer, CDK11(p110), in the tumorigenesis of human breast cancer remains unclear.
|
25990212 |
2015 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CDK11 and CK2 expression are individually essential for breast cancer cell survival, including TNBC.
|
25837326 |
2015 |